Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CBLB | Q13191 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | PDE2A | O00408 | 11/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16261251 | 0.86 | CNR1 (0.46) | NPSR1CNR1PDE2AL3MBTL1ALDH1A1 | |
| SCHEMBL22550861 | 0.84 | NPSR1 (0.44) | NPSR1PDE2AMLYCDHDAC4KDM4E | |
| SCHEMBL21199850 | 0.80 | SMN1; SMN2 (0.43) | IRAK4KDM4EALDH1A1HPGD | |
| SCHEMBL18168037 | 0.77 | RBP4 (0.41) | CBLBL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL23023554 | 0.76 | CBLB (0.45) | NPSR1CBLBCNR1PDE2AMLYCD | |
| SCHEMBL16261254 | 0.72 | NPSR1 (0.63) | NPSR1MLYCD | |
| SCHEMBL22540909 | 0.72 | NPSR1 (0.41) | NPSR1PDE2AL3MBTL1MLYCDHDAC4 | |
| SCHEMBL23023546 | 0.72 | JAK2 (0.45) | CNR1PDE2A | |
| SCHEMBL10271821 | 0.70 | HSP90AA1 (0.52) | L3MBTL1KDM4EALDH1A1HPGD | |
| SCHEMBL5433498 | 0.70 | LMNA (0.58) | NPSR1MLYCDHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020210508-A1 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS | NURIX THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |